J. Kuhlin

Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.

D. Touw, M. Sturkenboom, R. Koster, 2019, Clinical mass spectrometry.

Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma.

Biao Xu, J. Paues, J. Bruchfeld, 2020, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Impact of pyrazinamide resistance on multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan.

J. Hajek, D. Moore, J. Achar, 2018, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

Prospective evaluation of improving fluoroquinolone exposure using centralised therapeutic drug monitoring (TDM) in patients with tuberculosis (PERFECT): a study protocol of a prospective multicentre cohort study

S. Heysell, G. Sotgiu, Simon Tiberi, 2020, BMJ Open.

Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study

Biao Xu, Y. Hu, J. Paues, 2018, BMJ Open.

Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China

Biao Xu, J. Paues, J. Bruchfeld, 2020, European Respiratory Journal.

Genotypic resistance of pyrazinamide but not MIC is associated with longer time to sputum culture conversion in patients with multidrug-resistant tuberculosis.

J. Bruchfeld, J. Jonsson, R. Groenheit, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The impact of pyrazinamide resistance upon the treatment outcome of patients with multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan

J. Hajek, D. Moore, J. Achar, 2017 .